Researchers may be a step closer to developing a vaccine against the Epstein-Barr virus (EBV), a widespread virus associated with infectious mononucleosis, multiple sclerosis, certain cancers, and other serious illnesses.
The findings, published in Cell Reports Medicine, demonstrate the successful testing of laboratory-developed antibodies in mice.
About Epstein–Barr Virus (EBV)
- Also known as Human Herpesvirus 4 (HHV-4)
- Member of the herpes virus family
- Infects nearly 95% of the global population
- Usually acquired in childhood
- Often asymptomatic or causes mild illness
- In adolescents and adults, may cause infectious mononucleosis
- Linked to certain cancers and autoimmune conditions such as multiple sclerosis
EBV-associated lymphomas are particularly dangerous for immunosuppressed individuals, including organ transplant recipients.
Key Scientific Findings
Using mice engineered to carry human antibody genes, researchers developed 10 monoclonal antibodies targeting two viral surface proteins:
- gp350 – Helps the virus bind to cell receptors
- gp42 – Enables the virus to enter cells
One monoclonal antibody targeting gp42 successfully prevented EBV infection in mice with human immune systems when exposed to the virus.
Potential Clinical Implications
The study suggests that monoclonal antibody infusions could potentially:
- Prevent EBV infection
- Block viral activation in high-risk individuals
- Reduce EBV-related cancers and transplant complications
While further research and human trials are required, the findings represent a significant advance toward an effective EBV vaccine and targeted immunotherapy.
Source; DD
![](https://www.gstimes.in/wp-content/uploads/2024/03/MARCH-2024-GS-TIMES-1ADD.jpg")
